High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules

Background: The aim of this study was to investigate the discordance rates of eight known driver mutations among multiple matched intrapulmonary ground-glass nodules (GGNs) in non–small-cell lung cancer (NSCLC) patients. Methods: Tumors from 35 patients with multiple lesions resected, including confirmed NSCLC and at least one GGN, were analyzed for mutations in EGFR, KRAS, HER2, BRAF, and PIK3CA together with fusions in ALK, ROS1, and RET. Results: From 35 patients, a total of 72 lesions (60 were GGNs) were analyzed. These included nine adenocarcinoma in situ, nine minimal invasive adenocarcinoma, and 54 invasive adenocarcinoma. Among them, 33 tumor lesions (45.8 %) were found harboring EGFR mutations: 13 tumors with exon 19 deletion, 18 with L858R on exon 21, and two with both exon 19 del and L858R mutation. There were 5 tumors (6.9 %) harboring EML4-ALK fusion, four HER2 mutations (5.6%), three KRAS mutations (4.2%), one ROS1 fusion and one BRAF mutation. When we used the matched tumors to determine the intertumor discrepancy, only six out of 30 patients harbored identical mutations. The discordance rate of driver mutations was 80% (24 of 30) in those patients harboring at least one of the detected driver mutations. The median disease-free survival was 41.2 months (95% confidence interval: 35.8–52.6 months) and the median overall survival was “still not reached” in this cohort. Conclusions: We found a high discrepancy of driver mutations among NSCLC patients with GGNs and a favorable prognosis after multiple lesions resection, which support surgical resection in this situation as a reasonable approach.

[1]  Travis M. Drucker,et al.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Guotong Xu,et al.  Epithelial phenotype as a predictive marker for response to EGFR‐TKIs in non‐small cell lung cancer patients with wild‐type EGFR , 2014, International journal of cancer.

[3]  E. Chae,et al.  Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  Yang Zhang,et al.  Synchronous Non-small Cell Lung Cancers: Diagnostic Yield can be Improved by Histologic and Genetic Methods , 2014, Annals of Surgical Oncology.

[5]  Jingyun Shi,et al.  T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. , 2014, Lung cancer.

[6]  F. Hirsch,et al.  Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  G. Jiang,et al.  Surgical algorithm for heterogeneous bilateral quadruple pulmonary nodules. , 2013, Interactive cardiovascular and thoracic surgery.

[8]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[9]  C. Zhou,et al.  ROS1 fusions in Chinese patients with non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  F. Detterbeck,et al.  Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[11]  A. Chang,et al.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[12]  Caicun Zhou,et al.  KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer , 2013, Cancer.

[13]  荒井 淳一 Clinical and molecular analysis of synchronous double lung cancers , 2013 .

[14]  Qinghua Zhou,et al.  Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2013, PloS one.

[15]  T. Mok,et al.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.

[16]  S. Ren,et al.  Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma , 2012, Cell Biochemistry and Biophysics.

[17]  S. Ren,et al.  Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma , 2012, Cancer.

[18]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[19]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[20]  F. Detterbeck,et al.  Approach to the ground-glass nodule. , 2011, Clinics in chest medicine.

[21]  D. Clark,et al.  EGFR and KRAS mutations in metastatic lung adenocarcinomas. , 2011, Human pathology.

[22]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  C. Lee,et al.  Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Yong Soo Choi,et al.  Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Jae Ho Lee,et al.  Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Myrna C B Godoy,et al.  Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. , 2009, Radiology.

[27]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[28]  P. Jänne,et al.  Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Tae Jung Kim,et al.  Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. , 2009, Lung cancer.

[30]  K. Iyama,et al.  Epidermal Growth Factor Receptor Mutations in Multicentric Lung Adenocarcinomas and Atypical Adenomatous Hyperplasias , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  G. Rossi,et al.  A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. , 2008, American journal of clinical pathology.

[32]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[33]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.

[34]  Kenji Suzuki,et al.  A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. , 2003, The Annals of thoracic surgery.

[35]  D. Shibata,et al.  c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. , 1994, The American journal of pathology.

[36]  Yoshiro,et al.  Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. , 1994, The American journal of pathology.

[37]  M. Ferguson,et al.  Synchronous primary lung cancers. , 1993, Chest.

[38]  Kyung Soo Lee,et al.  Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. , 2013, Chest.

[39]  N. Girard,et al.  Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. , 2010, Chest.

[40]  F. Detterbeck,et al.  Lung cancer. Special treatment issues. , 2003, Chest.